At noon on March 26, CHINARES PHARMA announced on the Hong Kong Stock Exchange that in 2024, the group recorded total revenue of 257.6733 billion yuan, a year-on-year increase of 5.3%; net income was 8.4032 billion yuan, a year-on-year increase of 8.1%; net income attributable to the company owners was 3.3509 billion yuan, a year-on-year decrease of 13.1%.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
U.S. stock market closing | Concerns over tariffs and inflation pressured the three major indexes, with the Nasdaq falling nearly 3%; Google and Palantir dropped nearly 5%; NVIDIA's "favorite child" CoreWeave's debut was a rollercoaster.
Weekend reading | The path to POP MART's trillion goal: being an agent for LABUBU, expanding product categories, and going to the large market.
This week in Hong Kong stocks | The Innovative Drugs Sector in Hong Kong has exploded! Tongyuan Kang Pharmaceutical surged 25% this week, while 3SBIO rose nearly 19%; TCL ELECTRONICS exceeded expectations with a cumulative increase of nearly 20% this week
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
华润医药:2024年公司拥有人应占溢利33.5亿元,同比减少13.1%
CHINARES PHARMA: In 2024, net income attributable to the company owners is 3.35 billion yuan, a decrease of 13.1% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 221
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report